Serum/Cell marker Related cancer Targeted treatment (inhibitor/mAb)

CD3 Muromomab (S/E: flu-like syndrome)

Axicabtagene、Ciloleucel (CAR-T)
CD19 ALL
Blinatumomab (CD3-CD19 bispecific Ab)

CD20 CLL Rituximab、Obinutuzumab

CD25 Basiliximab、Daclizumab

CD33 AML Gemtuzumab

CD30 HL Brentuximab

CD38 Daratumumab
Multiple myeloma
SLAMF7 Elotuzumab

CD52 CLL Alemtuzumab

CD80:86 (B7) Abatacept

CD99 Ewing sarcoma

CD117 Germ cell tumor

PAS(+)、DPAS(+) Clear cell carcinoma

Bcl-2 AML、17p del. CLL Venetoclax

JAK1/2 MPN (PV、ET、PMF)、RA Ruxolitinib (JAK2)、Tofacitinib

GEN1: Imatinib

Tyrosine kinase Phil. Chr. (CML > ALL > AML) GEN2: Dasatinib/Bosutinib/Nilotinib

GEN3: Ponatinib

Bruton tyrosine kinase

MCL、CLL、WM Ibrutinib、Acalabrutinib、Zanubrutinib
(Btk)

Phosphoinositide
CLL、relapsed B-NHL Idelalisib、Copanlisib、Umbralisib
3-kinase (PI3K)

26s proteasome MM、MCL Bortezomib (-zomib)

PD-1 Pembrolizumab、Nivolumab

PD-L1 Atezolizumab、Avelumab、Durvalumab

CTLA-4 Ipilimumab

C5 PNH Eculizumab

IL-1 RA Anakinra、Canakinumab (IL-1β)

IL-2

IL-6 Tocilizumab

Thalidomide、Etanercept、Infliximab、Adalimumab、
TNF-α MM (Thal.)、RA、AS、Crohn disease
Golimumab、Certolizumab pegol
 IgG

IgE asthma Omalizumab

Fetal fibrosarcoma、high-grade glioma、 (New concept: Tumor-agnostic therapy)

NTRK gene fusion
lung ca.、colon ca.、thyroid ca. TRK inhibitor: Larotrectinib

B 細胞 surface marker: CD19  HLD-DR  CD10  CD20  SIg

位 脾/淋巴結（濾泡區）
Bone marrow(骨髓) → 脾/淋巴結（GC）→ 離開淋巴結/濾泡間
置 →

異 Precursor B-cells Peripheral (mature) B-cells

階 Pro B→Pre B→immature B →mature B →activated B →memory B /plasma cell

段
X CD5 X
展
X CD19 X
現
X CD20 X
抗
X CD22 X
原
CD52 X

造 Precursor B-cell neoplasm Pre-GC neoplasms GC neoplasms Post-GC neoplasms

疾 B-ALL, CLL, PLL FL, Burkitt, Mantle HL, DLBL, WM Multiple myeloma (MM)
病

T 細胞 surface marker: CD7  CD1a  CD2  CD5 CD3  CD4/8  CD4 or CD8